AstraZeneca Secures $65M Non-Dilutive Royalty Monetization Deal with Compugen
Compugen extended its cash runway to 2029 through a $65M non-dilutive royalty monetization deal securing future payments from AstraZeneca. The agreement preserves up to $195M in milestone royalties for the TIGIT-targeting asset rilvegostomig while avoiding equity dilution.
1. Deal Overview
Compugen extended its cash runway to 2029 by monetizing future royalty rights from AstraZeneca in a $65M non-dilutive transaction that avoids equity issuance and secures stable funding for ongoing operations.
2. Rilvegostomig Royalties and Milestones
The agreement preserves Compugen’s majority royalty interests in the TIGIT-targeting bispecific asset rilvegostomig, which now carries up to $195M in potential milestone payments based on clinical and regulatory progress.
Related News
GS
Oil Prices Rebound to $99–$106 After Trump Iran Deal Comments, Inventories Drop
GS•
BMY
Bristol Myers Squibb to Deploy Anthropic’s Claude AI Across 30,000 Employees
BMY•
GOOGL
Bill Ackman Cuts Alphabet Stake 95% to Fund Microsoft and Amazon Buys
GOOGL•
TSM
Samsung to Grant $340,000 Average Bonus to 78,000 Chip Workers
TSM•
BP
BP Raises Indonesian PSCs to 11 with Bintuni, Drawa and 49% Barong Stake
BP•
Sources
FFG